VC Profile: Jeito Capital in final stretch of biotech fund deployment
At a time when many big-ticket GPs are buying up specialist life science investors, France-based Jeito Capital is focused on staying an independent investor as it gears up to deploy the remaining third of its EUR 534m debut fund, founder Rafaèle Tordjman tells Unquote.
More on GPs
Advent raises USD 25bn for GPE X
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
Sun European acquires DD Group in carve out from IDH
Vendor Palamon said deal is phase one of returning IDH to pureplay dentistry, will invest proceeds in M&A
The Bolt-Ons Digest – 23 May 2022
Unquote’s selection of the latest add-ons featuring Nordic's Advanz, H2's Optegra, Sovereign's Zenitech, Carlyle's Dept, and more
Palatine bolsters impact and buyout teams
Rupert Brown moves to the impact team after promotion; Carly Sinicrope joins from Clearwater as investment manager
Latest News
Perusa to exit Müpro in SBO to IK
Management of the German industrial fixings supplier will reinvest with a minority stake
Ufenau acquires EinzelNet in first deal with Fund VII
Management and founders will retain a 25% stake in the Spanish IT services group; bolt-ons planned under new owner
Advent raises USD 25bn for GPE X
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
MB Funds to exit Raksystems in sale to Trill Impact
New majority owner will seek to expand the Finnish green building services specialist across Europe